Mikhail Blagosklonny

Mikhail Blagosklonny
Fields Anti-aging medicine, oncology
Institutions Roswell Park Cancer Institute
Alma mater First Pavlov State Medical University of St. Peterburg

Mikhail Blagosklonny is a scientist who studies cancer and aging. He was formerly a professor of oncology at the Roswell Park Cancer Institute in New York.[1]

Career

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Peterburg.[1] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009 when he was appointed professor of oncology at Roswell Park Cancer Institute.[1]

Blogosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[1]

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[2] He is considered one of the most passionate advocates for rapamycin in longevity research.[3]

Editorial activities

Blagosklonny is editor-in-chief of Aging,[4] Cell Cycle,[5] and Oncotarget.[6] In addition, he is associate editor of Cancer Biology & Therapy[7] and a member of the editorial board of Cell Death & Differentiation.[8]

The reviewing process employed by Oncotarget has been criticized by Jeffrey Beall,[9] who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[10] in July 2015.[9] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editor-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal impact factor.[11]

Selected publications

Blagosklonny has published over 270 papers in peer-reviewed journals with over 25,000 citations, giving him an h-index of 83.[12]

References

  1. 1 2 3 4 Roswell Park Cancer Center Mikhail Blagosklonny profile Page accessed November 30, 2016
  2. ↑ "A New Path to Longevity". Scientific American. 306: 32–39. 2011. doi:10.1038/scientificamerican0112-32. Retrieved 2016-11-20.
  3. ↑ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis’s push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
  4. ↑ "Editorial Board". Aging. Retrieved 2016-11-20.
  5. ↑ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
  6. ↑ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  7. ↑ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  8. ↑ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
  9. 1 2 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. WordPress.com. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  10. ↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. WordPress.com. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  11. ↑ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.
  12. ↑ "Mikhail Blagosklonny". Google Scholar. Google. Retrieved 2016-11-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.